EUVIMEDEUVIMED entdecken
Crossref

Moving Closer to Personalized Cancer Prevention Strategies by Assessing Comorbidity and Multimorbidity

Siran M Koroukian, Uriel Kim, Johnie Rose

JAMA Network Open · 07.04.2025 · 8 (4) · e253476

DOI: 10.1001/jamanetworkopen.2025.3476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 07.04.2025. Verfasst von Siran M Koroukian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the current issue of JAMA Network Open , the observational study by Lavery et al 1 separately analyzed the association between comorbidities in midlife and incidence of cancer (all types), incidence of 19 individual cancer types, and cancer mortality. The study leveraged data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial, which included approximately 130000 individuals with a median follow-up period of 20 years. For ease of interpretation, the 12 self-reported comorbid conditions were classified into 5 distinct categories. Lavery and colleagues 1 found that comorbidities were associated with developing multiple individual cancers. For example, individuals with cardiovascular disease had higher risk of developing kidney, biliary, and upper gastrointestinal cancers. In addition, history of respiratory, cardiovascular, and metabolic conditions was associated with greater hazard of cancer death. However, comorbidities were weakly associated with overall cancer risk. The association of certain comorbidities with relatively lower risk of developing specific cancers (eg, decreased risk of prostate cancer in men with a history of gastrointestinal conditions) may be due to residual confounding. The authors should be commended for their innovative use of data from the PLCO screening trial to examine these associations, as this is, to our knowledge, the first large-scale epidemiological study analyzing comorbidities in midlife in relation to subsequent cancer incidence, complementing previous studies that have documented a co-occurrence of and shared risk factors between heart failure and cancer, as an example. 2 While the literature is replete with studies analyzing demographic, behavioral, dietary, environmental, and other risk factors in relation to cancer incidence, rarely have studies analyzed comorbidities as a risk factor for specific cancers, especially in midlife. Despitetheimportantadvancementthatthisstudybringstoourunderstandingofcancerrisk,we needtofurtherimproveourmethodsofaccountingforcoexistingconditions.AsnotedbyValderasand

Autor:innen und Institutionen

  • Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio.
  • Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
  • Center for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, Ohio.

Zitieren

APA

Koroukian, S. M., Kim, U., & Rose, J. (2025). Moving Closer to Personalized Cancer Prevention Strategies by Assessing Comorbidity and Multimorbidity. JAMA Network Open, 8(4), e253476. https://doi.org/10.1001/jamanetworkopen.2025.3476

Vancouver

Koroukian SM, Kim U, Rose J. Moving Closer to Personalized Cancer Prevention Strategies by Assessing Comorbidity and Multimorbidity. JAMA Network Open. 2025;8(4):e253476. doi:10.1001/jamanetworkopen.2025.3476

BibTeX
@article{Koroukian2025,
  author = {Koroukian, Siran M and Kim, Uriel and Rose, Johnie},
  title = {Moving Closer to Personalized Cancer Prevention Strategies by Assessing Comorbidity and Multimorbidity},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {4},
  pages = {e253476},
  doi = {10.1001/jamanetworkopen.2025.3476}
}
Kostenlos starten →